Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs.
Saved in:
| Title: | Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs. |
|---|---|
| Authors: | Jelinek T; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.; Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.; Sylvester Comprehensive Cancer Center, Myeloma Research Institute, University of Miami, Miami, FL., Zihala D; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.; Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.; Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic., Zabaleta A; Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain., Kostopoulos IV; Department of Biology, School of Sciences, National and Kapodistrian University of Athens, Athens, Greece., Soucek O; Department of Immunology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic., Venglar O; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.; Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Moreno C; Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain., Fotiou D; Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece., Radova E; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.; Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Tamariz-Amador LE; Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain., Theodorakakou F; Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece., Muronova L; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.; Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Manubens A; Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain., Tsitsilonis O; Department of Biology, School of Sciences, National and Kapodistrian University of Athens, Athens, Greece., Popkova T; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.; Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Gonzalez C; Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain., Anilkumar Sithara A; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.; Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.; Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic., Corrado F; Center for Early Detection and Interception, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Bidikian N; Center for Early Detection and Interception, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Guerrero C; Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain., Kapustova V; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.; Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Bilek D; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.; Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.; Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic., Hagner PR; Bristol Myers Squibb, Summit, NJ., Larrayoz M; Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain., Martinez Climent JA; Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain., Broskevicova L; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.; Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Mihalyova J; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.; Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Merz M; Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Sevcikova T; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.; Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.; Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic., Ghobrial IM; Center for Early Detection and Interception, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., San Miguel J; Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain., Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.; Department of Medicine, Korea University, Seoul, South Korea., Rodriguez-Otero P; Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain., Radocha J; Fourth Department of Internal Medicine-Hematology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic., Kastritis E; Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece., Paiva B; Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain., Hajek R; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.; Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. |
| Source: | Blood [Blood] 2026 Mar 05; Vol. 147 (10), pp. 1070-1082. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
